期刊
NATURE REVIEWS IMMUNOLOGY
卷 22, 期 2, 页码 77-84出版社
NATURE PORTFOLIO
DOI: 10.1038/s41577-021-00665-1
关键词
-
类别
资金
- Intramural Research Program of the US National Institute of Diabetes and Digestive and Kidney Diseases [ZIA/DK075149]
- US National Heart, Lung, and Blood Institute [ZIA/Hl006223]
- FWO COVID-19 grant
- COVID-19 grant from the Fondazione Italcementi Cav. Lav. CARLO PESENTI
Hyperactivation of the complement system is implicated in the pathology of COVID-19, with potential therapeutic benefits through complement inhibition. Latest research progress suggests targeting complement components for treatment may be beneficial in mitigating excessive inflammation and thrombosis in severe COVID-19 cases.
Hyperactivation of the complement and coagulation systems is recognized as part of the clinical syndrome of COVID-19. Here we review systemic complement activation and local complement activation in response to the causative virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and their currently known relationships to hyperinflammation and thrombosis. We also provide an update on early clinical findings and emerging clinical trial evidence that suggest potential therapeutic benefit of complement inhibition in severe COVID-19. Hyperactivation of the complement system has been implicated in the pathology of COVID-19. Here the authors bring together the latest information on the role of complement in COVID-19 and progress in targeting complement components for treatment of severe disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据